Kyntra Bio, Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 06 Oct 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 09 Apr 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Kyntra Bio, Inc. — Overview & Financial Snapshot
Kyntra Bio, Inc. (NasdaqGS: KYNB) is a Healthcare company, ranked #6,463 of 6,774 companies globally and #3,718 of 4,000 in United States on PositoAI, with a Positivity Score of -20,362. Its market capitalisation is ₹199.51 Cr ($21.14M), P/E ratio is -0.7 and P/B ratio is -0.70. It currently has 2 active red flags (PosiRed) and no yellow flags (PosiYellow) on record.
For financial statements, ratio trends and score history, Go Deep →